Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $62,000.

  • Lyell Immunopharma's Capital Expenditures rose 5.08% to $62,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $520,000, marking a year-over-year increase of 16.85%. This contributed to the annual value of $464,000 for FY2024, which is 82.73% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Capital Expenditures stood at $62,000, which was down 63.10% from $168,000 recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Capital Expenditures high stood at $24.4 million for Q2 2021, and its period low was $25,000 during Q4 2023.
  • Its 3-year average for Capital Expenditures is $329,636, with a median of $168,000 in 2025.
  • As far as peak fluctuations go, Lyell Immunopharma's Capital Expenditures crashed by 99.45% in 2023, and later spiked by 76.00% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Capital Expenditures (Quarterly) stood at $10.3 million in 2021, then crashed by 55.38% to $4.6 million in 2022, then slumped by 99.45% to $25,000 in 2023, then surged by 76.00% to $44,000 in 2024, then rose by 5.08% to $62,000 in 2025.
  • Its Capital Expenditures was $62,000 in Q3 2025, compared to $168,000 in Q2 2025 and $246,000 in Q1 2025.